3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
245
Precursor Cell Lymphoblastic Leukemia-Lymphoma
143
Myelodysplastic Syndromes
142
Leukemia, Lymphocytic, Chronic, B-Cell
139
Leukemia
127
Multiple Myeloma
117
Lymphoma
115
Lymphoma, Non-Hodgkin
112
Recurrence
79
Hematologic Neoplasms
74
Melanoma
68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Hodgkin Disease
67
Lymphoma, B-Cell
61
Lymphoma, Mantle-Cell
51
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Burkitt Lymphoma
41
Ovarian Neoplasms
40
Neoplasms
39
Myeloproliferative Disorders
39
Neoplasm Metastasis
34
Lymphoma, B-Cell, Marginal Zone
30
Graft vs Host Disease
29
Neoplasms, Plasma Cell
28
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
27
Leukemia, Biphenotypic, Acute
25
Primary Myelofibrosis
24
Anemia, Refractory, with Excess of Blasts
23
Interventions
Carboplatin
69
Paclitaxel
47
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
36
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
ceritinib
5
capmatinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Mastectomy, Segmental
5
Cyclophosphamide
5
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma of Lung
×
fludarabine
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn